Project Grant R01CA301579
Award Date
6/23/25
Completion Date
5/31/30
Dollars Obligated
$642K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award for $547,020.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish an Organoid-AI system for assessing cardiotoxicity induced by Tyrosine Kinase Inhibitors (TKIs) used in cancer treatment. The central goal is to develop a comprehensive in vitro human model using Pluripotent Stem Cell-derived Vascularized Cardiac Organoids (VCOs) to accurately predict and phenotype...
This Project Grant award from the National Science Foundation (NSF) under the Computer and Information Science and Engineering (CFDA 47.070) program provides $275,956 to develop an engineered cyber-physical system that combines advanced biological models with artificial intelligence methods for predictive, automated screening of anti-cancer drugs and optimizations of their dosing. The project aims to create a generalized, self-dose-optimizing multi-sensor-integrated multi-organ-on-a-chip...
This National Science Foundation Project Grant of $606,649 will support the development of an engineered cyber-physical system combining advanced biological models and artificial intelligence methods to enable precision medicine for cancer treatment. Awarded under the Computer and Information Science and Engineering program, the funding will be used by Brigham and Women's Hospital and its parent organization Partners Healthcare System from October 2022 to September 2025. Specifically, the...
This $989,122 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to evaluate the performance of four commercial mammography-based artificial intelligence (AI) algorithms for breast cancer risk prediction in diverse U.S. screening populations. The project will assess the accuracy and equity of these AI risk models compared to traditional clinical risk factor-based models, using data from the Breast Cancer...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) at the National Institutes of Health provides $167,864 to The Leland Stanford Junior University to investigate risk stratification and outcomes across the spectrum of cardiotoxicity from immune checkpoint inhibitor cancer therapies. The study aims to: 1) retrospectively examine cardiac and oncologic outcomes associated with immune checkpoint inhibitor cardiotoxicity based on...
The National Cancer Institute awarded a $684,333 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Trustees of Columbia University in the City of New York. The project, titled "Integrating Breast Cancer and Cardiovascular Disease Risk to Explore Decision-Making for Chemoprevention Among Racially/Ethnically Diverse Women at High Risk for Breast Cancer," aims to evaluate if patient and provider decision support that juxtaposes breast cancer...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $155,657 to the University of Arkansas for Medical Sciences (UAMS) to conduct a study on disparities in cardiovascular toxicity among breast cancer survivors in Arkansas. The key objectives are to: 1) Identify disparities in cardiovascular toxicity among breast cancer survivors based on race, ethnicity, neighborhood socioeconomic...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,000,000 to Novomedix LLC, a woman-owned small business in San Diego, CA, to conduct definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients receiving anthracycline chemotherapy. The overall goal is to develop a safe and effective therapy that...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports a $644,804 research project titled "Advancing Breast Cancer Risk Assessment for Black Women." The project aims to develop and validate a novel deep learning-based breast cancer risk assessment tool focused on Black women, leveraging digital breast tomosynthesis (DBT) imaging data. Key objectives include: Developing a DBT-driven...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,604 to Case Western Reserve University to develop and validate a novel transfer volume regression model. This model aims to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The project will leverage commonly used, low-cost screening programs to...